Tag Archives: GIST

Qinlock (Ripretinib) Approved as Fourth-Line Treatment for GIST

MONDAY, May 18, 2020 — The U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as a fourth-line treatment for adults with advanced gastrointestinal stromal tumors (GISTs), the agency announced Friday. The approval follows four other FDA-approved target therapies for GIST, including imatinib in 2002, sunitinib in 2006, regorafenib in 2013, and avapritinib in January.… Read More »